Rudy Ochs
Family Medicine · Hart, MINPI 1669418356
Payments from drug & device makers
Across 251 payments — averaging $11.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$392
- Pfizer$348
- AstraZeneca$307
- AbbVie$271
- Merck$209
- Amgen$185
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,921100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $392 |
| Pfizer | 38 | $348 |
| AstraZeneca | 17 | $307 |
| AbbVie(2 entities) | 31 | $271 |
| Merck | 17 | $209 |
| Amgen | 11 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $177 |
| Amarin Pharma, Inc. | 8 | $130 |
| GSK | 33 | $125 |
| Otsuka America Pharmaceutical, Inc. | 7 | $103 |
| Novartis | 7 | $95 |
| Boehringer Ingelheim | 6 | $89 |
| Lundbeck LLC | 4 | $60 |
| Mylan Specialty L.p. | 4 | $58 |
| Ironshore Pharmaceuticals Inc. | 3 | $57 |
| Johnson & Johnson | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Medtronic | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
How this compares
$2,921 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $105,121 |
| FarxigaDapagliflozin Propanediol | 118 | $92,484 |
| OzempicSemaglutide | 79 | $71,297 |
| JardianceEmpagliflozin | 61 | $52,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $45,410 |
| EntrestoSacubitril/Valsartan | 45 | $35,334 |
| MounjaroTirzepatide | 32 | $34,107 |
| JanuviaSitagliptin Phosphate | 40 | $28,157 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $27,711 |
| XareltoRivaroxaban | 27 | $21,838 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 40 | $19,458 |
| LinzessLinaclotide | 26 | $14,078 |
| Repatha SureclickEvolocumab | 19 | $11,075 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $9,969 |
| Spiriva RespimatTiotropium Bromide | 18 | $8,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $89 | $108,268173 claims |
| PfizerEliquis | $348 | $105,121134 claims |
| AstraZenecaFarxiga, Symbicort | $307 | $97,930140 claims |
| Novo NordiskOzempic | $392 | $71,29779 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $125 | $55,37988 claims |
| NovartisEntresto | $95 | $35,33445 claims |
| Lilly USA, LLCMounjaro | $15 | $34,10732 claims |
| MerckJanuvia | $209 | $28,15740 claims |
| Johnson & JohnsonXarelto | $51 | $21,83827 claims |
| AbbVieLinzess | $271 | $14,07826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Hart
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.